Multiple Sclerosis Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- A safety report was submitted to the trial sponsor (using specific medical coding terms related to a virus called JC virus or a brain condition called Progressive Multifocal Leukoencephalopathy, or PML) between 4 June 2026 and 31 July 2041
- The safety report came from a source such as a voluntary post-market report, a post-market observational study that collected its own data, or a patient support program
- The person had a diagnosis of multiple sclerosis before the safety report was filed
- The person had received at least one dose of a medication called ozanimod before any PML symptoms began
- An independent review committee assessed the PML case as either "definite" or "probable"
- The same independent review committee assessed the PML case as being related to ozanimod
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- No additional exclusion criteria have been specified for this trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of progressive multifocal leukoencephalopathy (PML) cases by participant characteristics and potential risk factors among ozanimod-exposed participants with multiple sclerosis
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.